Synergistic Pemafibrate Dosing Regimens with AI, IoT, Blockchain, and Novel Materials

The present inventive concept integrates pemafibrate dosing regimens with cutting-edge technologies like AI, IoT, blockchain, and novel materials to create a more effective, personalized, and secure system for treating dyslipidemia.

The original patent disclosed pemafibrate dosing regimens for treating dyslipidemia, but these regimens lacked the benefits of modern technologies. The present inventive concept addresses this limitation by combining pemafibrate with AI-driven patient health monitoring, IoT-enabled medication adherence tracking, blockchain-based patient data storage, and novel nanoparticle delivery systems, thereby enhancing treatment outcomes, improving patient safety, and reducing healthcare costs.

The inventive concept comprises five synergistic combinations: (1) a blockchain-based patient data storage module, a machine learning-based pemafibrate efficacy prediction module, and an IoT-enabled medication adherence tracking module; (2) integrating pemafibrate dosing regimens with AI-driven patient health monitoring and real-time OATP1B inhibitor interaction alerts; (3) a pemafibrate-based medicament with a novel nanoparticle delivery system and a companion AI-powered diagnostic tool for personalized treatment planning; (4) a blockchain-secured pemafibrate dosing regimen management system with a decentralized patient data repository and a smart contract-based medication adherence incentive program; and (5) a synergistic combination of pemafibrate and a novel OATP1B inhibitor, comprising a co-formulated oral dosage form and a companion AI-driven pharmacokinetic modeling tool for optimizing treatment outcomes. These combinations enable personalized treatment planning, real-time patient monitoring, and secure data management, ultimately leading to improved treatment outcomes and reduced healthcare costs.

The present inventive concept introduces a novel integration of pemafibrate dosing regimens with AI, IoT, blockchain, and novel materials, which is not obvious from the original patent. The inventive concept's synergistic combinations provide a new and non-obvious solution to the problem of optimizing pemafibrate treatment outcomes, enhancing patient safety, and reducing healthcare costs.

Alternative embodiments of the inventive concept may include different AI algorithms for patient health monitoring, various IoT devices for medication adherence tracking, or alternative blockchain platforms for patient data storage. Variations of the inventive concept may also include different nanoparticle delivery systems or OATP1B inhibitors, which could be co-formulated with pemafibrate to enhance treatment outcomes.

The present inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of dyslipidemia. The market for pemafibrate-based medicaments is expected to grow significantly, and the inventive concept's integration with AI, IoT, blockchain, and novel materials is likely to capture a substantial share of this market. Potential commercial applications include personalized treatment planning, real-time patient monitoring, and secure data management, ultimately leading to improved treatment outcomes and reduced healthcare costs.